Presentation Stock market days at Aktiespararna
June, 2025
Presenter:
Martin Åmark, CEO
Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.
We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.
We develop biosimilars in treatment of macular degeneration (Xlucane™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion
June, 2025
Presenter:
Martin Åmark, CEO
24 Nov 2025
Xbrane Biopharma resolves to issue 420,517 warrants to Fenja Capital II A/S under the conditional financing solution
19 Nov 2025
XBRANE UPDATES ON TIMING FOR RESUBMISSION OF THE BLA FOR ITS RANIBIZUMAB BIOSIMILAR CANDIDATE TO FDA
03 Nov 2025
THE NUMBER OF SHARES AND VOTES IN XBRANE HAS CHANGED AS A RESULT OF THE PREVIOUSLY ANNOUNCED REVERSE SPLIT OF 1:125.
28 Oct 2025
Siavash Bashiri sells shares to repay loan taken in connection with the 2024 rights issue, but remains a dedicated and long-term employee and shareholder